Dr. Pangan is a board-certified rheumatologist with 20 years of industry experience in clinical development and medical affairs. She joined Merck in Feb 2022 to head the new Immunology Clinical Research Therapeutic Area. Prior to Merck, she was Executive Medical Director/Global Development Leader, Immunology Clinical Development at Abbvie where she led a clinical team of 16 MDs/PhDs through design and execution of phase 2-3 programs in rheumatology, gastroenterology and dermatology, global regulatory filings and approvals of multiple indications for upadacitinib (RINVOQ). She previously led phase 3 programs in rheumatology and ophthalmology for adalimumab (HUMIRA) which also led to regulatory filings and approvals. She also spent 5 years in Global Medical Affairs where she was the Rheumatology global team lead supporting HUMIRA. Prior to joining industry, Dr. Pangan was Assistant Professor of Medicine in an academic Rheumatology practice at Loyola University Medical Center in Chicago. She completed her rheumatology clinical and research fellowship at Massachusetts General Hospital/Harvard Medical School, and her internal medicine residency at Rush University Medical Center. Dr. Pangan has previously served as Corporate Representative to the Board of Directors of the Rheumatology Research Foundation, and as a member of the Development Advisory Council and the National Advisory Council. She also previously served on the Committee on Research of the American College of Rheumatology.